Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
I'm PortAI, I can summarize articles.
Yi Chen from H.C. Wainwright reiterated a Buy rating on NeuroPace, citing promising NAUTILUS trial results. The trial showed a 77% reduction in seizures among patients with drug-resistant epilepsy. Despite not meeting the primary endpoint, secondary improvements were significant, suggesting potential FDA conditional approval. The stock has a price target of $18.00, supported by Breakthrough Device designation and unmet patient needs. Lake Street also affirmed a Buy rating with a $20.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments